VEGFA and neoplasm: In addition to antibody-based interventions, broad-spectrum tyrosine kinase inhibitors such as sunitinib—which concurrently inhibit VEGF and platelet-derived growth factor (PDGF) receptors—have shown efficacy in preclinical models by disrupting angiogenic signaling and reducing tumor mass (45).